MediPal Holdings Corporation (MAHLY) key stats comparison: compare with other stocks by metrics: valuation, growth, profitability, momentum, EPS revisions, dividends, ratings. Skip to content Home ...

View the latest MAHLY financial statements, income statements and financial ratios. Medipal Holdings Corp. ADR Annual stock financials by MarketWatch. Skip to main content ...

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

1 Day MAHLY 1.82% DJIA -0.61% S&P Mid Cap 400 -0.18% Retail/Wholesale -1.62% ...

Insider Trading information for NDAQ is derived from Forms 3 and 4 filings filed with the U.S. Securities and Exchange Commission (SEC). Please Note:An FPI is exempt of filing insider holdings ...

**NM signifies a non meaningful value. A dash signifies the data is not available.

Get today's Medipal ADR stock news. We cover the latest Medipal ADR headlines and breaking news impacting Medipal ADR stock performance.

TOKYO & HYOGO, Japan, May 07, 2025--MEDIPAL and JCR announced that the U.S. FDA granted orphan drug designation (ODD) to JR-446, an investigational drug for the treatment of MPS IIIB. MEDIPAL HOLDINGS ...

Reveal insider sentiment with alternative data that tracks buy and sell trades made by top managers and company directors.

*Close price adjusted for splits.**Close price adjusted for splits and dividend and/or capital gain distributions. Loading more data ...